Exclusive: GenLight Secures Hundreds of Millions of RMB, Closing Two Financing Rounds in Quick Succession

Recently, Hangzhou Genlight Neurotech Co., Ltd., a data-driven full-stack brain-computer interface platform company, announced the completion of consecutive Series C and D financing rounds, with cumulative funding reaching hundreds of millions of RMB.

Series C was led by Qiming Venture Partners, with existing shareholders Hangzhou Yuhang Financial Holdings Group and CD Capital continuing their investment, and Tailong Capital, PuXin Capital, Jianyuan Xizheng, Lingang Life Blue Bay Fund, Yufu Gaozhi Fund, and Hehe Venture Capital following on. Series D saw the joint participation of Saizhibole, Kuanqiao Hengsong, Ningbo state capital, and other institutions.

Following the financing, GenLight will continue to invest around commercialization and internationalization: accelerating the registration, launch, and commercialization of Epilcure™; advancing the clinical translation of Vivastep™ and other next-generation neural interface products; and further improving its brain science data and algorithm platform. In overseas markets, it will pursue international registrations such as FDA and CE and global clinical collaborations, leveraging its dual-center layout of Hangzhou and Singapore to progressively build an international product and clinical collaboration system.

For GenLight, the core objective of the next stage has shifted from proving technical feasibility to proving product value, expanding clinical applications, and building commercialization capability.

Brain-computer interfaces represent the hard-tech summit integrating materials, chips, AI algorithms, neuroscience, precision engineering, and other disciplines, with extremely high technical barriers. The industry widely believes that, as policy support, rigid clinical needs, AI algorithms, implantable hardware, and precision manufacturing capabilities mature, the competitive focus of the BCI industry is shifting from single-point technological breakthroughs to platform capabilities that can be reused across disciplines, products, and scenarios. This financing round sends a clear signal: BCI is moving from frontier technology exploration into a new stage where clinical validation and industrial deployment proceed in parallel.

Founded in 2020 with headquarters in Hangzhou and an international center in Singapore, GenLight upholds the vision of "Brain to Beyond | Starting from the Brain, Transcending Boundaries," focusing on precision diagnosis and treatment of brain disorders, closed-loop neuromodulation, and brain health management. It is one of the representative companies in this industry.

The LaserRO™ MRI-monitored semiconductor laser therapy system developed by GenLight has obtained a national Class III medical device registration certificate, completing the full product delivery journey from special review for innovative medical devices and clinical validation to registration and market launch. Through preoperative imaging planning, stereotactic implantation, and real-time MRI thermal imaging monitoring, the system performs precise laser ablation of intracranial lesions, offering a minimally invasive treatment option for drug-resistant epilepsy and brain lesions; its dual-wavelength laser, real-time temperature monitoring, and preoperative planning technologies further enhance the precision and controllability of ablation therapy.

The S-Deep™ intracranial depth electrode (SEEG) system developed by the company has obtained a national Class III medical device registration certificate, and is used for intracranial EEG signal acquisition and precise epilepsy localization, serving as an important neural interface for implantable BCI systems. Through these products, GenLight has formed product synergy across neural signal acquisition, precise localization, and neuromodulation, laying the foundation for the clinical application of future closed-loop BCI products.

The Epilcure™ implantable BCI neurostimulation system developed by GenLight targets drug-resistant focal epilepsy: through implantable electrodes, it continuously monitors intracranial EEG activity, and upon identifying abnormal EEG signals, automatically initiates responsive stimulation, achieving closed-loop neuromodulation based on EEG sensing.

The product entered the special review procedure for innovative medical devices in 2022, completed enrollment of 110 patients in its confirmatory clinical trial in 2025, and has accumulated more than 120 clinical implants to date.

Unlike traditional open-loop neurostimulation, Epilcure™ integrates EEG sensing, abnormal signal recognition, and stimulation intervention into a single system, evolving neuromodulation from fixed-parameter stimulation toward individualized, responsive therapy.

At the same time, the company is continuously accumulating long-term intracranial EEG data, providing the data foundation for patient condition assessment, treatment strategy optimization, and subsequent product iteration.

Building on closed-loop neuromodulation, GenLight has further extended its technology into the motor function restoration field.

The Vivastep™ closed-loop spinal cord neural interface system targets patients with spinal cord injury and paralysis, integrating epidural spinal cord electrical stimulation, neural signal decoding, and closed-loop adaptive modulation technologies. Through the synergistic mechanism of "neural signal sensing – stimulation modulation – motor training," it helps patients recover the ability to stand and walk.

In 2025, the company completed China's first implant of a closed-loop spinal cord neural interface in a patient, who regained independent standing and walking within two months after surgery; in 2026, the company completed closed-loop spinal cord neural interface implantation treatment for an overseas paraplegic patient, marking an important step in its internationalization. The program has now completed nearly 20 clinical implants.

GenLight's core competitiveness is not limited to a single product. The company has built a deeply integrated "smart hardware + multimodal data + AI large model" three-in-one technology system, forming full-chain R&D capabilities covering smart hardware, underlying algorithms, system platforms, and clinical applications.

Within this system, all products at the smart hardware layer are developed from two proprietary technology foundations: the STEMII precision neurosurgery technology platform focuses on precision neurosurgical intervention, covering key links including preoperative planning, stereotaxis, neural interface implantation, precise localization, and minimally invasive treatment, providing underlying technical support for products such as S-Deep™ and LaserRO™; the BCMod brain-computer interface neuromodulation platform focuses on neural signal sensing, signal processing, intelligent decoding, and closed-loop neuromodulation, supporting the continued R&D and clinical translation of implantable neural interface products such as Epilcure™ and Vivastep™.

At the multimodal data and AI large model level, the combination of BCI and AI is giving rise to an emerging data asset — intracranial neural signal data.

This type of data comes directly from inside the brain, with signal-to-noise ratios far exceeding scalp EEG, and is continuously accumulated through long-term implantation, capturing the complete dynamic process before and after changes in neural states.

Leveraging its multimodal data accumulation, GenLight has integrated AI model capabilities into neural signal sensing, state recognition, and modulation decision-making, building vertical model capabilities around the EEG cloud platform, neural stimulation parameter optimization, and personalized treatment plan recommendation, evolving its products from "signal acquisition" toward "understanding signals, responding to signals, and continuously optimizing based on feedback."

For implantable closed-loop BCI products represented by Epilcure™, as clinical data continue to accumulate, algorithm models and stimulation strategies will be further iterated and optimized, making the products "smarter with use," with post-delivery commercial value continuing to grow alongside therapeutic iteration.

This "neural interface – data – AI model – closed-loop modulation" technology path enables GenLight to support different diseases and different neuromodulation scenarios on a unified technology foundation, establishing the basis for continued product development and technology reuse. Moreover, as brain science data and AI model capabilities mature, its application boundaries can further extend to non-medical scenarios such as brain health management and brain-machine intelligent interaction, opening up greater application space for BCI technology.

For invasive BCI, technological breakthroughs are only the starting point of industrialization. For products to truly enter clinical use, they require the joint support of long-term clinical validation, regulatory approval, manufacturing systems, hospital access, and commercialization capabilities.

Currently, GenLight has obtained four national Class III medical device registration certificates, three of which are innovative medical device certificates, with products covering key links including EEG acquisition, precise localization, and minimally invasive treatment.

On the clinical front, the company has established a clinical collaboration network with more than 50 tertiary Grade A hospitals nationwide, continuously carrying out multicenter clinical studies and product applications. The company has filed more than 400 intellectual property applications and obtained more than 190 granted patents. Through innovation platforms such as the Zhejiang Provincial Engineering Research Center for Clinical Brain-Computer Interfaces and the Zhejiang Provincial Key Laboratory of Pain Perception and Neuromodulation, it continues to strengthen its neural interface, algorithm, and clinical translation capabilities.

As its core products progressively enter the registration and launch stage, the company has completed the building of medical affairs, clinical support, market access, and commercialization teams, fully advancing products from R&D toward hospital application.